13 september 2022: ESMO 2022

Afgelopen week was er ESMO 2022. Hier een aantal aanbevolen abstracten door Rafael Fonseca MD. Abstracten gerelateerd aan verschillende vormen van kanker maar die zijn opgevallen door de resultaten. 

Ook David Henry MD geeft een aantal aanbevolen abstracten, zie verder in dit artikel.

De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2022 gaat kunt u via de nummers van de abstracten deze vinden.

Friday, September 9, 2022
14:00–15:30 CEST; Proffered Paper Session
Gynaecological Cancers

LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). IL Ray-Coquard

Friday, September 9, 2022
14:00–15:30 CEST; Proffered Paper Session
CNS Tumours

279O ctDNA detection in cerebrospinal fluid and concordance with the primary tumor in a multicenter prospective study of patients with glioma. S Cabezas-Camarero

Friday, September 9, 2022
16:00–17:30 CEST; Proffered Paper Session
Breast Cancer, Metastatic

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). M Goetz

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). HS Rugo

Saturday, September 10, 2022
10:15 AM–11:45 AM CEST; Proffered Paper Session 1
GU Tumours, Non-Prostate

LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. A Bex

Saturday, September 10, 2022
10:15 AM–11:45 AM CEST; Proffered Paper Session
Sarcoma

1484O Deep learning predicts patients’ outcome and mutations from H&E slides in gastrointestinal stromal tumor (GIST). R Perret

Saturday, September 10, 2022
14:45–16:15 CEST; Mini Oral Session
Investigational Immunology

736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS). CK Kyi

Sunday, September 11, 2022
8:30 AM–10:00 AM CEST; Proffered Paper Session
GU Tumours, Prostate

LBA62 Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): overall survival (OS) results of 2 randomised Phase III trials from the STAMPEDE protocol. G Attard

Sunday, September 11, 2022
14:45–16:15 CEST; Proffered Paper Session 2
GI, Upper Digestive

LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. A Hollebecque

Monday, September 12, 2022
10:15–11:45 CEST; Proffered Paper Session 2
Melanoma and Other Skin Tumours

788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915). GV Long

Friday, September 9, 2022
14:00–15:30 CEST; Proffered Paper Session
Gynaecological Cancers

LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). IL Ray-Coquard

Friday, September 9, 2022
14:00–15:30 CEST; Proffered Paper Session
CNS Tumours

279O ctDNA detection in cerebrospinal fluid and concordance with the primary tumor in a multicenter prospective study of patients with glioma. S Cabezas-Camarero

Friday, September 9, 2022
16:00–17:30 CEST; Proffered Paper Session
Breast Cancer, Metastatic

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). M Goetz

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). HS Rugo

Saturday, September 10, 2022
10:15 AM–11:45 AM CEST; Proffered Paper Session 1
GU Tumours, Non-Prostate

LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. A Bex

Saturday, September 10, 2022
10:15 AM–11:45 AM CEST; Proffered Paper Session
Sarcoma

1484O Deep learning predicts patients’ outcome and mutations from H&E slides in gastrointestinal stromal tumor (GIST). R Perret

Saturday, September 10, 2022
14:45–16:15 CEST; Mini Oral Session
Investigational Immunology

736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS). CK Kyi

Sunday, September 11, 2022
8:30 AM–10:00 AM CEST; Proffered Paper Session
GU Tumours, Prostate

LBA62 Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): overall survival (OS) results of 2 randomised Phase III trials from the STAMPEDE protocol. G Attard

Sunday, September 11, 2022
14:45–16:15 CEST; Proffered Paper Session 2
GI, Upper Digestive

LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. A Hollebecque

Monday, September 12, 2022
10:15–11:45 CEST; Proffered Paper Session 2
Melanoma and Other Skin Tumours

788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915). GV Long

Ook David Henry MD geeft een aantal aanbevolen abstracten

Friday, September 9, 2022
14:00–15:30 CEST; Proffered Paper Session
Gynaecological Cancers

LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). IL Ray-Coquard

  • Previously, this trial has shown positive progression-free survival; so, hopefully, overall survival will be positive as well.

Friday, September 9, 2022
16:00–17:30 CEST; Proffered Paper Session
Breast Cancer, Metastatic

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). M Goetz

  • Previously, this trial has shown positive progression-free survival; so, hopefully, overall survival will be positive as well.

Saturday, September 10, 2022
8:30–9:50 CEST; Proffered Paper Session 1
GI, Upper Digestive

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). RS Finn

  • This trial prob did not hit its primary endpoint; but, we will see when it is presented.

Saturday, September 10, 2022
10:15 AM–11:45 AM CEST; Proffered Paper Session 1
GU Tumours, Non-Prostate

LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. A Bex

  • This is likely to be a positive trial.

LBA67 Phase III RandOmized Study Comparing PErioperative Nivolumab (nivo) versus Observation in Patients (Pts) with Renal Cell Carcinoma (RCC) Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. M Allaf

  • This is likely to be a positive trial.

Saturday, September 10, 2022
ePosters; Early Breast Cancer

142P Effectiveness and safety of pegylated liposomal doxorubicin- cyclophosphamide vs. epirubicin-cyclophosphamide as adjuvant chemotherapy for stage I and II HER2-negative breast cancer: An interim analysis of phase II randomized trial. L-M Tseng

  • This is a much safer, better-tolerated preparation of doxorubicin in liposomal form, and results here were comparable, suggesting that treaters may prefer this anthracycline over epirubicin in early-stage breast cancer.

153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC). PF Conte

  • This interesting outcome predictor in early-stage grade II positive breast cancer combines a gene score and a clinical score to give better distant metastasis–free survival information for predicting outcome from adjuvant therapy with or without chemotherapy.

Sunday, September 11, 2022
8:30–10:00 CEST; Proffered Paper Session
Non-Metastatic NSCLC and Other Thoracic Malignancies

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC): updated results from ADAURA. M Tsuboi

  • Likely to be a positive trial

Sunday, September 11, 2022
8:30–10:00 CEST; Proffered Paper Session
Supportive and Palliative Care

1552O Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxane-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial. L Michel

  • Hopefully, something to help our patients with this “taxing” problem

Sunday, September 11, 2022
10:15–11:45 CEST; Mini Oral Session
NSCLC, Metastatic

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. K Goto

  • Another use of this incredible antibody–drug conjugate in any HER2-positive tumor

Sunday, September 11, 2022
10:15 AM–11:45 AM CEST; Proffered Paper Session 1
GI, Lower Digestive

LBA21 FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group. MJ Bond

  • A positive trial

 


Plaats een reactie ...

Reageer op "ESMO 2022. Aanbevolen abstracten voor verschillende vormen van kanker door Dr. Rafael Fonseca die opvielen op ESMO 2022"


Gerelateerde artikelen
 

Gerelateerde artikelen

ESMO 2022. Aanbevolen abstracten >> Geneesmiddel (ARS1620) verandert >> Repotrectinib, een TRK remmer, >> Tweede primaire vorm van kanker >> Blaaskanker: Biomarkers als >> 6 nieuwe doorbraken in de >> CDK4 en 6-remmers - palbociclib, >> Overzicht van studies met >> Vaccin tegen KRAS positief >> Kankerremmende eiwitten kunnen >>